Global Wealth Management Investment Advisory Inc. Sells 824 Shares of Johnson & Johnson $JNJ

Global Wealth Management Investment Advisory Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,867 shares of the company’s stock after selling 824 shares during the period. Johnson & Johnson accounts for about 1.0% of Global Wealth Management Investment Advisory Inc.’s investment portfolio, making the stock its 28th largest position. Global Wealth Management Investment Advisory Inc.’s holdings in Johnson & Johnson were worth $5,326,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. GFG Capital LLC bought a new stake in Johnson & Johnson during the second quarter valued at about $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. purchased a new position in shares of Johnson & Johnson in the first quarter worth $65,000. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $186.50 on Friday. The stock has a market cap of $449.34 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a 50 day moving average price of $184.25 and a 200-day moving average price of $168.70. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is currently 50.19%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Citigroup boosted their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.